Effects of antiparkinsonian agents on β‐amyloid and α‐synuclein oligomer formation in vitro |
| |
Authors: | Kenjiro Ono Jun‐ichi Takasaki Ryoichi Takahashi Tokuhei Ikeda Masahito Yamada |
| |
Affiliation: | 1. Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, , Kanazawa, Japan;2. Department of Neurology, National Hospital Organization Iou Hospital, , Kanazawa, Japan |
| |
Abstract: | The aggregation of β‐amyloid protein (Aβ) and α‐synuclein (αS) are hypothesized to be the key pathogenic event in Alzheimer's disease (AD) and Lewy body diseases (LBD), with oligomeric assemblies thought to be the most neurotoxic. Inhibitors of oligomer formation, therefore, could be valuable therapeutics for patients with AD and LBD. Here, we examined the effects of antiparkinsonian agents (dopamine, levodopa, trihexyphenidyl, selegiline, zonisamide, bromocriptine, peroxide, ropinirole, pramipexole, and entacapone) on the in vitro oligomer formation of Aβ40, Aβ42, and αS using a method of photo‐induced cross‐linking of unmodified proteins (PICUP), electron microscopy, and atomic force microscopy. The antiparkinsonian agents except for trihexyphenidyl inhibited both Aβ and αS oligomer formations, and, among them, dopamine, levodopa, pramipexole, and entacapone had the stronger in vitro activity. Circular dichroism and thioflavin T(S) assays showed that secondary structures of Aβ and αS assemblies inhibited by antiparkinsonian agents were statistical coil state and that their seeding activities had disappeared. The antiparkinsonian agents could be potential therapeutic agents to prevent or delay AD and LBD progression. © 2013 Wiley Periodicals, Inc. |
| |
Keywords: | β ‐amyloid protein α ‐synuclein oligomer antiparkinsonian agents |
|
|